시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 디지털 치료제(DTx) 시장 분석 및 예측(-2034년) : 유형, 제품, 서비스, 기술, 컴포넌트, 용도, 디바이스, 전개, 최종 사용자
Digital Therapeutics (DTx) Market Analysis and Forecast to 2034: Type, Product, Services, Technology, Component, Application, Device, Deployment, End User
상품코드 : 1699196
리서치사 : Global Insight Services LLC
발행일 : 2025년 04월
페이지 정보 : 영문 422 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,666,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 8,069,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,472,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

세계의 디지털 치료제(DTx) 시장은 2024년 78억 달러에서 2034년까지 568억 달러로 확대되어 CAGR 약 22%를 보일 것으로 예측됩니다. DTx 솔루션은 데이터 분석 및 맞춤형 의료를 활용하여 만성 질환, 정신 건강, 생활 습관병을 목표로 삼고 있습니다.

시장 개요:

디지털 치료제(DTx) 시장은 만성 질환의 만연과 비용 효과적인 건강 관리 솔루션에 대한 수요 증가에 힘입어 견조한 확대를 이어가고 있습니다. 시장을 리드하고 있는 것은 소프트웨어 기반 솔루션으로, 높은 접근성, 기존 의료 시스템과의 통합의 용이성, 맞춤 치료 개입을 제공할 수 있는 점 등이 우위성을 발휘하고 있습니다. 인지 행동 치료 애플리케이션 및 정신 건강 관리를 위한 디지털 플랫폼과 같은 신흥 하위 부문은 정신 건강 문제에 대한 인식을 높이고 확장 가능한 원격 관리 솔루션에 대한 요구를 배경으로 인력을 늘리고 있습니다. 또한 인공지능과 머신러닝 기술의 DTx에의 통합은 치료의 개별화와 유효성에 혁명을 가져오는 태세를 갖추고 있습니다.

시장 세분화
유형 소프트웨어 기반, 하드웨어 기반, 콤비네이션 제품
제품 처방전 디지털 치료사, 비처방형 디지털 치료사
서비스 컨설팅, 교육, 교육, 지원 및 유지보수
기술 인공지능, 머신러닝, 사물 인터넷(IoT), 블록체인, 클라우드 컴퓨팅
구성요소 소프트웨어, 하드웨어
용도 당뇨병, 심혈관 질환, 중추 신경계 질환, 호흡기 질환, 금연, 비만증, 약물 사용 장애
장치 웨어러블 디바이스, 핸드헬드 디바이스, 데스크톱 디바이스
배포 온프레미스, 클라우드 기반
최종 사용자 환자, 건강 관리 제공업체, 지불자, 고용주

디지털 치료학(DTx) 시장은 기술을 활용하여 증거 기반 치료 개입을 제공하는 혁신적인 헬스케어 솔루션에 대한 수요 증가가 주요 요인이 되고 있습니다. 북미는 견고한 헬스케어 인프라와 유리한 상환 정책에 힘입어 DTx 도입의 최전선에 있습니다. 한편, 유럽과 아시아태평양은 헬스케어 지출 증가와 디지털 변환 이니셔티브에 의해 가속도적인 성장을 목격하고 있습니다. 시장 경쟁은 Pear Therapeutics, Omada Health, Akili Interactive와 같은 전략적 파트너십과 기술적 진보를 통해 지속적으로 제품 제공을 강화하는 주요 기업의 존재를 특징으로 하고 있습니다. 향후, DTx 시장은 인공지능이나 머신러닝의 진보에 의해 디지털 치료 솔루션의 퍼스널라이제이션과 유효성의 향상이 기대되고, 대폭적인 성장이 예상됩니다.

주요 동향과 촉진요인

디지털 치료제(DTx) 시장은 만성질환의 만연과 개인화된 헬스케어 솔루션에 대한 수요 증가에 힘입어 견조한 확대를 이어가고 있습니다. 주요 동향은 DTx 플랫폼에 인공지능과 머신러닝을 통합하여 환자 참여와 치료 결과를 향상시키는 것입니다. 게다가, 모바일 헬스 용도의 대두는 디지털 치료가 보다 친숙해지고, 편리한 헬스케어의 선택지를 요구하는 하이테크에 익숙한 환자의 요구에 부응하고 있습니다. 각국 정부가 의료비 절감과 환자 케어 개선에 있어서의 DTx의 가능성을 인식하고 있기 때문에 규제 당국의 지원과 유리한 상환 정책이 시장 성장을 더욱 뒷받침하고 있습니다. 하이테크 기업과 의료 서비스 제공업체 간의 협업은 혁신을 촉진하고 진보된 디지털 개입의 개발로 이어지고 있습니다. 예방 헬스케어의 중시도 DTx의 보급을 뒷받침하고 있어, 개인의 건강 관리가 보다 적극적으로 되고 있습니다. 디지털 인프라가 급속히 정비되고 헬스케어 시스템의 디지털 변혁이 진행되는 신흥 시장에는 기회가 넘쳐나고 있습니다. 확장 가능하고 비용 효율적인 솔루션을 제공할 수 있는 기업은 큰 시장 점유율을 확보할 수 있을 것으로 보입니다. 디지털 치료의 장점에 대한 인식이 높아짐에 따라 만성 질환 관리 및 정신 건강 치료가 크게 발전 할 수 있으며 시장은 지속적인 성장이 예상됩니다.

억제요인과 도전:

디지털 치료제(DTx) 시장에는 몇 가지 심각한 억제요인과 과제가 있습니다. 기존 의료 시스템에 DTx를 통합하는 것은 복잡하며 전자 의료 서비스 및 기타 디지털 건강 플랫폼과의 상호 운용성을 보장하기 위해 상당한 시간과 리소스가 필요하므로 환자에 대한 액세스가 제한되어 명확한 경제적 리턴을 요구하는 이해관계자의 투자 의욕이 감퇴하고 있는 것도 덧붙여지고 있습니다. 또한, 시장은 헬스케어 전문가와 환자 양쪽으로부터 회의론에 직면하고 있어 기존 치료와 비교해 디지털 개입의 유효성과 신뢰성을 의문시할 가능성이 있습니다. 민감한 건강 정보의 수집과 관리에는 사용자의 신뢰를 얻기 위한 견고한 보안 조치가 필요하기 때문에 데이터 프라이버시에 대한 우려도 커다란 과제가 되고 있습니다.

목차

제1장 디지털 치료제(DTx) 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 디지털 치료제(DTx) 시장 전망

제5장 디지털 치료제(DTx) 시장 전략

제6장 디지털 치료제(DTx) 시장 규모

제7장 디지털 치료제(DTx) 시장 : 유형별

제8장 디지털 치료제(DTx) 시장 : 제품별

제9장 디지털 치료제(DTx) 시장 : 서비스별

제10장 디지털 치료제(DTx) 시장 : 기술별

제11장 디지털 치료제(DTx) 시장 : 컴포넌트별

제12장 디지털 치료제(DTx) 시장 : 용도별

제13장 디지털 치료제(DTx) 시장 : 디바이스별

제14장 디지털 치료제(DTx) 시장 : 전개별

제15장 디지털 치료제(DTx) 시장 : 최종 사용자별

제16장 디지털 치료제(DTx) 시장 : 지역별

제17장 경쟁 구도

제18장 기업 프로파일

JHS
영문 목차

영문목차

Digital Therapeutics (DTx) Market is anticipated to expand from $7.8 billion in 2024 to $56.8 billion by 2034, growing at a CAGR of approximately 22%. The market encompasses software-driven interventions delivering evidence-based therapeutic outcomes, often complementing or replacing traditional treatments. DTx solutions target chronic conditions, mental health, and lifestyle diseases, leveraging data analytics and personalized medicine. This market is propelled by technological advancements, increased healthcare digitization, and a growing emphasis on preventive care, promising significant improvements in patient engagement and health outcomes.

Market Overview:

The Digital Therapeutics (DTx) Market is experiencing robust expansion, fueled by the increasing prevalence of chronic diseases and the rising demand for cost-effective healthcare solutions. The leading market segment is the software-based solutions, which dominate due to their accessibility, ease of integration with existing healthcare systems, and ability to deliver personalized therapeutic interventions. These solutions leverage advanced algorithms and data analytics to provide tailored treatment plans, enhancing patient outcomes and adherence. Emerging sub-segments, such as cognitive behavioral therapy applications and digital platforms for mental health management, are gaining traction, driven by the growing awareness of mental health issues and the need for scalable, remote care solutions. Additionally, the integration of artificial intelligence and machine learning technologies into DTx is poised to revolutionize treatment personalization and efficacy. The potential impact of these innovations is significant, promising to expand the market's reach and improve the quality of healthcare delivery globally.

Market Segmentation
TypeSoftware-based, Hardware-based, Combination Products
ProductPrescription Digital Therapeutics, Non-prescription Digital Therapeutics
ServicesConsultation, Training and Education, Support and Maintenance
TechnologyArtificial Intelligence, Machine Learning, Internet of Things (IoT), Blockchain, Cloud Computing
ComponentSoftware, Hardware
ApplicationDiabetes, Cardiovascular Diseases, Central Nervous System Disorders, Respiratory Diseases, Smoking Cessation, Obesity, Substance Use Disorders
DeviceWearable Devices, Handheld Devices, Desktop Devices
DeploymentOn-premises, Cloud-based
End UserPatients, Healthcare Providers, Payers, Employers

The Digital Therapeutics (DTx) market is predominantly driven by the increasing demand for innovative healthcare solutions that leverage technology to deliver evidence-based therapeutic interventions. The market is segmented into various application areas, including diabetes, obesity, cardiovascular diseases, and mental health, with mental health applications demonstrating significant traction due to the rising awareness and acceptance of digital health solutions. North America remains at the forefront of DTx adoption, bolstered by a robust healthcare infrastructure and favorable reimbursement policies, while Europe and Asia-Pacific are witnessing accelerated growth due to increasing healthcare expenditure and digital transformation initiatives. The competitive landscape is characterized by the presence of key players such as Pear Therapeutics, Omada Health, and Akili Interactive, who are continuously enhancing their product offerings through strategic partnerships and technological advancements. Regulatory frameworks, particularly in the United States and Europe, are evolving to accommodate the unique nature of DTx, with initiatives like the FDA's Digital Health Software Precertification Program paving the way for streamlined approval processes. Looking ahead, the DTx market is poised for substantial growth, driven by advancements in artificial intelligence and machine learning, which are expected to enhance the personalization and efficacy of digital therapeutic solutions. However, challenges such as data privacy concerns and the need for robust clinical evidence remain, necessitating ongoing innovation and collaboration across the industry.

Geographical Overview:

The Digital Therapeutics (DTx) market is witnessing diverse growth patterns across regions, each with unique characteristics. North America stands at the forefront, propelled by robust healthcare infrastructure and high digital health adoption. The region benefits from strong regulatory support and significant investments in healthcare innovation. Europe follows closely, with an emphasis on integrating digital health solutions into traditional healthcare systems. The region's commitment to patient data security and privacy enhances trust and adoption. In Asia Pacific, the DTx market is expanding rapidly, driven by increasing healthcare digitization and rising chronic disease prevalence. Governments are investing in digital health to improve access to care. Latin America and the Middle East & Africa are emerging markets with growing potential. Latin America is experiencing increased digital health investments, while the Middle East & Africa are recognizing the importance of DTx in addressing healthcare challenges. These regions are gradually adopting digital therapeutics, encouraged by supportive policies and initiatives aimed at enhancing healthcare delivery.

Recent Development:

In recent months, the Digital Therapeutics (DTx) market has experienced notable developments across various dimensions. Firstly, Pear Therapeutics announced a strategic partnership with a leading pharmaceutical company to enhance the distribution of its FDA-approved digital therapies, aiming to broaden patient access and improve health outcomes. Secondly, Akili Interactive unveiled its latest cognitive therapeutic platform, designed to address cognitive impairments in children, marking a significant innovation in pediatric digital health solutions. Meanwhile, a merger between two prominent DTx companies was finalized, promising to consolidate resources and accelerate the development of cutting-edge digital health interventions. Regulatory advancements were also seen as the European Medicines Agency introduced new guidelines to streamline the approval process for digital therapeutics, potentially expediting market entry for innovative solutions. Lastly, the market witnessed a significant investment surge, with venture capitalists injecting substantial funds into emerging DTx startups, underscoring the growing investor confidence in the sector's potential to revolutionize healthcare delivery.

Key Trends and Drivers:

The Digital Therapeutics (DTx) market is experiencing robust expansion, spurred by the growing prevalence of chronic diseases and the increasing demand for personalized healthcare solutions. A key trend is the integration of artificial intelligence and machine learning within DTx platforms, enhancing patient engagement and treatment outcomes. Additionally, the rise of mobile health applications is making digital therapies more accessible, catering to the needs of tech-savvy patients seeking convenient healthcare options. Regulatory support and favorable reimbursement policies are further driving market growth, as governments recognize the potential of DTx in reducing healthcare costs and improving patient care. Collaborations between tech companies and healthcare providers are fostering innovation, leading to the development of sophisticated digital interventions. The emphasis on preventive healthcare is also propelling the adoption of DTx, as individuals become more proactive in managing their health. Opportunities abound in emerging markets, where digital infrastructure is rapidly improving, and healthcare systems are undergoing digital transformation. Companies that can offer scalable, cost-effective solutions stand to gain significant market share. As awareness of the benefits of digital therapeutics grows, the market is poised for sustained growth, with potential for significant advancements in chronic disease management and mental health treatment.

Restraints and Challenges:

The Digital Therapeutics (DTx) market is experiencing several significant restraints and challenges. A primary challenge is regulatory uncertainty, as varying global regulations create barriers to entry and complicate compliance processes. This inconsistency hampers the ability of companies to scale their solutions internationally. Furthermore, the integration of DTx into existing healthcare systems is complex, requiring significant time and resources to ensure interoperability with electronic health records and other digital health platforms. Another restraint is the limited reimbursement frameworks, which restrict patient access and discourage investment from stakeholders who seek clear financial returns. Additionally, the market faces skepticism from both healthcare professionals and patients, who may question the efficacy and reliability of digital interventions compared to traditional treatments. Data privacy concerns also pose a significant challenge, as the collection and management of sensitive health information necessitate robust security measures to gain user trust. Finally, the rapid pace of technological advancements in this field demands continuous innovation, which can strain resources and hinder long-term stability.

Key Companies:

Pear Therapeutics, Akili Interactive, Omada Health, Click Therapeutics, Happify Health, Big Health, Propeller Health, Cognoa, Kaia Health, Well Doc, Mind Maze, Limbix, Biofourmis, Mahana Therapeutics, Lark Health, Hinge Health, Blue Mesa Health, Mightier, Otsuka Digital Health, Voluntis

Sources:

World Health Organization (WHO), U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Digital Therapeutics Alliance (DTA), International Society for Digital Medicine (ISDM), Health Level Seven International (HL7), Global Digital Health Partnership (GDHP), American Medical Association (AMA), European Health Telematics Association (EHTEL), International Telecommunication Union (ITU), World Economic Forum (WEF) - Digital Health Initiative, Health Information and Management Systems Society (HIMSS), International Society for Telemedicine and eHealth (ISfTeH), European Commission - Directorate-General for Health and Food Safety, National Health Service (NHS) Digital, Japan Agency for Medical Research and Development (AMED), International Conference on Digital Health, National Institute for Health and Care Excellence (NICE)

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Digital Therapeutics (DTx) Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Digital Therapeutics (DTx) Market Outlook

5: Digital Therapeutics (DTx) Market Strategy

6: Digital Therapeutics (DTx) Market Size

7: Digital Therapeutics (DTx) Market, by Type

8: Digital Therapeutics (DTx) Market, by Product

9: Digital Therapeutics (DTx) Market, by Services

10: Digital Therapeutics (DTx) Market, by Technology

11: Digital Therapeutics (DTx) Market, by Component

12: Digital Therapeutics (DTx) Market, by Application

13: Digital Therapeutics (DTx) Market, by Device

14: Digital Therapeutics (DTx) Market, by Deployment

15: Digital Therapeutics (DTx) Market, by End User

16: Digital Therapeutics (DTx) Market, by Region

17: Competitive Landscape

18: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기